Journal of Clinical Psychopharmacology: February 14, 2020 – Volume Publish Ahead of Print – Issue –
doi: 10.1097/JCP.0000000000001179
“Taken together, these findings suggest that agents targeting elements of the ECS (cannabinoids) could modulate the aforementioned neurocognitive processes to improve OCD symptoms.”